

Monitoring and reporting on the drug use in Europe; The EMCDDA perspective on Khat

Paul Griffiths- October 2009, Linköping, Sweden

Confession

- Khat addict ...
 - Have tried very hard to escape its clutches but failed miserably
- Personally have limited expertise in this area
- The EMCDDA's perspective on Khat is simple to present as...



This presentation...

Brief introduction to EMCDDA

- Mission
- Scope of activities
- Monitoring approaches and tools
- Why Khat is a difficult topic for us

Explore what we can say in the EU about Khat

- What data are there on the availability use
- Khat in wider perspective of EU stimulant market & emerging trends

Conclusion

Why perhaps we should have a perspective on khat





Introduction to the EMCDDA

Who we are



- A decentralised EU agency
- Formally established in 1993
- Based in Lisbon, Portugal (operating since 1995)
- The hub of drug-related information in the EU
- About 100 staff; 22 nationalities; a budget of around 13.5 million Euros



What we do

Provide the Community and EU Member States with:

'factual, objective, reliable and comparable information at European level concerning drugs and drug addiction and their consequences'

New mission (2007) gives agency a broader role:

- collect, register, analyse information on 'emerging trends in polydrug use', including combined use of licit and illicit psychoactive substances
- provide information on best practice in Member States and facilitate exchange of such practice between them



Collecting and analysing data

Methods:

- Reitox national focal points (NFPs), national experts
- Annual reporting to EMCDDA (national reports, standard tables, questionnaires)
- Expert groups for developing indicators (nominated by NFPs)
- Ad hoc working groups





Scope of monitoring activities

- Epidemiology (drug situation incl. 5 Key Indicators)
- Supply & market information
- New threats & developments (council decision)
- Responses prevention, treatment, harm reduction & social reintegration
- Best practices
- Supply reduction activities
- Legislation (national and Community strategies and laws)
- Policy developments (political and institutional framework, coordination)



Khat information?

- Epidemiology (drug situation incl. 5 Key Indicators)
- Supply & market information
- New threats & developments (council decision)
- Responses prevention, treatment, harm reduction & social reintegration
- Best practices
- Supply reduction activities
- Legislation (national and Community strategies and laws)
- Policy developments (political and institutional framework, coordination)



Why Khat a difficult topic for us?

Historically has fallen into a grey area for us...

- Legal status (controlled V non controlled)
- Overall low prevalence & cultural-ethnic specificity – not a policy priority at EU level
- Rarely appears in standard quantitative data sets we use



EU level monitoring of drug use among ethnic minorities & migrant populations

Politically sensitive

- Legal status 'invisible population' politically may not exist
- Concern about encouraging stigmatisation & racism
- Links between some ethnic minorities & trafficking and supply complicates things further

Methodologically challenging

- Legal barriers and no consensus on definitions
- A lack of robust information sources
- Lack of specialist services in most countries
- EU added value? ... best done at national level?





What do we know about Khat availability & use in Europe?

Khat production



Khat is an **economically important plant** in the countries that cultivate it; for

Medical and social use goes back to antiquity: Yemen, Ethiopia, Somalia, Kenya

International trade, & migration khat use has spread to countries far away from areas of cultivation.

Every week tonnes of Kenyan khat reaches the UK by air for local use and distribution to other countries.

Available from websites and smart shops as 'room odoriser'.




Khat use in Europe

- No evidence of Khat use in general population (most surveys do not include this category) but...
- Use reported among East Africa migrants (Somali, Ethiopian, Kenyan and Yemeni)
- Some anecdotal evidence to suggest that limited diffusion may be occurring to other groups?
 (among UK students, Poly drug use)
- Seizures reported by some countries
- But not a commonly or regularly used stimulant in EU outside of specific populations



Global drug seizures, excluding cannabis, 2004-2005



Source: UNODC, WDR 2007



Legal situation

UN Conventions


- Khat itself is not controlled
- But its psychoactive compounds, cathine and cathinone are classed as Schedule III and Schedule I respectively under the UN Conventions (and controlled in all EU MS).
- National legislation determines if the plant is controlled
 - Parallel with magic mushrooms & legal grey area
- Plant controlled as narcotic drugs in at least 14 EU member states
 - Belgium, Denmark, Germany, France, Ireland, Italy, Lithuania, Slovenia, Finland, Sweden, Norway, Latvia, Greece, Poland



Khat seizures in the EU

- Main point of entry UK & NL
- Only 12 countries report seizures
 - in 2006 an estimated 1,200 seizures totalling 41 tonnes of Khat were reported
- Number seizures low
 - Typically less than 100
 - Sweden & Norway a bit higher
- Quantities
 - Fairly stable situation most countries reporting less 2,500KG
 - Over the period 2000–2006, quantities seized increased
 - Germany, Norway, Sweden important






Distribution of Khat from a UK perspective

Ethiopia 50% of people Yemen Kenya 61% of people The largest source use khat regularly of khat for the UK use khat regularly Air freiaht Holland and other European UK airports Via boat 5-7 tonnes arrives a day, the bulk in transit to the USA USA Is illegal here Cost \$400/kg By road Somali. Yemen and **Ethiopian Communities** Mafreshi Mobile Local Shops **Traders** Cost is £15/kg and markets (£3-5 a bundle) Street selling


Source: ACMD report, 2005



Number of seizures of Khat by country and year in some EU countries and Norway, 2000-2008.



Quatities siezed (kg.) of Khat by country and year in some EU countries and Norway, 2000-2008.





Khat as a new drug? Khat & related compounds in the EWS

EWS - Council Decision 2005/387/JHA: a three-step process

Information exchange/Early-warning

A new psychoactive substance is detected in the EU Member States and described in a reporting form

Europol national units

EMCDDA

The European Commission

European Medicines Agency (EMEA)

Risk assessment

The Council of the EU may request a risk assessment, based on a EMCDDA– Europol Joint report

EMCDDA extended Scientific Committee

Risk assessment report

Decision-making

At the initiative of the Council of the EU European Control decides whether or not Council Commission or a measures and to submit the new Decision **Member State** criminal psychoactive on control based on the Risk penalties in the substance to control measures assessment report **EU Member** measures States



EWS & new trends

- Globalisation, information technology & other technological advances important drivers
 - Mahajan & Miller (1994) creation of unified markets is associated with the faster diffusion of new ideas products & technologies
- Market actively seeking out new products
 - Sophisticated marketing
 - Innovation driven by cheap organic synthesis,
 - Difficulties of drug control in global market
 - Growing importance of the INTERNET



Spice: a recent example



- Herbal mixtures sold on the Internet & specialised shops around 2005?
- An 'exotic incense blend', 'not for human consumption'
- Reported by some users to have effects similar to cannabis
- Extensive forensic investigations by some Member States identified synthetic cannabinoids added to the herbal mixture (JWH-018, CP 47,497, HU-210) (2008)
- Mainly an Internet phenomenon
- Control measures: AT, DE, FR, LU, PL, EE, SE... (2008-9)
- New cannabinoids continue to appear following control measures



What is the potential of Khat as...

- A newly promoted psychoactive substance within the herbal highs market?
- A chemical group...within the context of developments in synthetic drug market in Europe?



Patterns of use, mode of action and effects

Patterns of use

- Fresh leaves, twigs & shoots are chewed (like coca leaf / tobacco chewing) and the
 juice of the masticated leaves is swallowed
- Typically, 100-300 g of khat (1 bundle) are used over a period of 3-4 h
- Dried khat is also ingested as an infusion
- Occasionally smoked

Mode of action

- Facilitates dopamine release
- Inhibits dopamine and norepinephrine re-uptake
- Affects the serotonin system

Psychostimulant effects

- Central nervous system stimulant
- Mildly euphoric and stimulant
- Insomnia, wakefulness
- Increased heart rate
- Decreased appetite






Fresh khat leaves




Dried khat leaves



















Effects peak after 15-30 min 98% metabolised by the liver

Fresh khat leaves

Cathinone




Unstable, potent

Schedule I drug, 1971 UN Convention Decomposition

48 hr
depotentiation of khat leaves over time

Dried khat leaves

Cathine



Milder

Schedule III drug, 1971 UN Convention




Half-life in humans ~ 3hr

Cathinones

cathinone (beta keto derivative of amphetamine)

amphetamine
(phenethylamine)



- Cathinones are pharmacologically active (stimulant) alkaloids extracted from the leaves of Khat plant (Catha edulis)
- When khat leaves are chewed, cathinone is metabolised by the liver into cathine, which is also present in khat
- These compounds are structurally and pharmacologically similar to amphetamine



Cathinones: Structural analogues of phenetylamines


Cathinones

Phenetylamines

$$O$$
 NH_2
 U
 U

Methylone

Methedrone (bk-PMMA)




MDMA



Cathinones sold as 'legal highs'

- 13 cathinones are being monitored by the EWS
- 6 of the 13 NPAS reported to the EWS in 2008 were cathinones
- 2 cathinones have been reported to the EWS in 2009 so far





Methylone

- First reported in NL at the end of 2004,
- Marketed under name Explosion
- Marketed as a vanilla-scented 'room odorizer', with the following warnings: 'do not ingest', 'keep away from children', 'never use more than one bottle.








Can Khat compete with other drugs on the EU stimulant market?

Perspective in EU stimulant market

- Strong stimulant market in Europe
- Cocaine, amphetamines, and drugs used in Europe but not as widely as cannabis synthetic
- Increase of cocaine use over the last years whereas amphetamines use steady (or even decreasing)
- Cocaine use prevails in west and south Europe whereas amphetamines use predominant in northern, central and eastern Member States
- Hypothesis of replacement of substances
- Could Khat play a future role?



Stimulant markets in the EU



Issues – barriers to Khat diffusion

Transportation

- Large volume
- Short product life

Pharmacological action


- need a lot
- Slow onset

Route administration

- Unfamiliar
- Stimulant drugs often used instrumentally (specific activities & settings)



Methamphetamine production facilities (2008)







Concluding remarks...

An EU perspective...

Trends

- Stimulant market IN EU robust but...
- Khat probably will not compete with main stimulants & trend is towards synthetic substances
- But some diffusion possible need for monitoring & research
- The chemical group is becoming increasingly important in the growing new synthetic drugs market

Reponses

- Whole area of drug use among migrant and ethnic communities becoming increasingly important at EU level
- Do not know much about problems associated with Khat use
- Generally care model for stimulant users is poorly developed in EU (but now changing)
- Control policies the trend is to become increasingly convergent & Khat is problematic from an EU perspective





www.emcdda.europa.eu